Analysis of Vectibix(R) Study Using New Gene Technology Helps to Advance Prospects for Personalized Medicine--Nine Genes Beyond KRAS Investigated As Potential Predictive Bioma...

Wed, 04/21/2010 - 1:21pm

THOUSAND OAKS, Calif., April 18, 2010 /PRNewswire via COMTEX/ --Amgen (Nasdaq: AMGN) today announced detailed results from a new biomarker analysis of the pivotal Phase 3 “408” trial of Vectibix(R) (panitumumab) plus best supportive care (BSC) compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer (mCRC). Highlighted results were presented at the opening press conference at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

Read the rest of this entry



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.